Physician profile
Eric Morgenstern
NPI 1093730210
$3,478.67
in general payments reported to CMS, 2019-2025
18 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $272 · 2021: $245 · 2022: $550 · 2023: $511 · 2024: $457 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,042.55 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $502.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $373.87 | 2019-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $273.85 | 2019-2023 | Dificid |
| Qol Medical, LLC | $266.19 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $224.33 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $211.45 | 2019-2020 | |
| Janssen Biotech, INC. | $101.06 | 2019-2023 | Stelara |
| Celgene Corporation | $95.68 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $80.11 | 2019 | |
| Ironwood Pharmaceuticals, INC | $52.73 | 2020-2022 | |
| Ardelyx, INC. | $51.58 | 2023 | Ibsrela |
| Pfizer INC. | $48.39 | 2024 | |
| Daiichi Sankyo INC. | $47.09 | 2019 | |
| Braintree Laboratories, INC. | $43.48 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.22 | 2024 | Dupixent |
| Alfasigma USA, INC. | $23.48 | 2020 | |
| Redhill Biopharma INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Morgenstern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.